UNSPSC 51162731: Oxedrine

This classification denotes an adrenergic alpha-agonist, nasal decongestant, sympathomimetic, and vasoconstrictor agent with the molecular formula C9H13NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PEG5DP7434, chemically known as benzyl alcohol, p-hydroxy-alpha-((methylamino)methyl)- but more generally known as oxedrine, which bears US NIH Compound Identifier 7172. European Medicines Agency schedules Oxedrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14726MIG.

World Health Organization schedules oxedrine in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, OXEDRINE remains US FDA's Preferred Term for this commodity. SMILES: OC(CNC)C1CCC(O)CC1.

UNSPSC 51162731 Oxedrine is a Commodity code under which state and local governments procure naloxone and pharmaceutical products for emergency medical response and community health initiatives. Recent solicitations show demand for naloxone kits and safe drug deactivation systems supplied through competitive bidding and cooperative purchasing arrangements, with vendors expected to deliver products meeting FDA compliance standards and cGMP certification requirements. State and local issuing bodies include county health departments and multistate cooperative purchasing alliances administering on behalf of multiple state and local member jurisdictions.

Activity spans Florida and the Upper Midwest, with Seminole County, Florida posting an IFB in June 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually under solicitation IFB60459723LAS (response deadline July 26, 2023), and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issuing an RFP in January 2026 for generic multi-source pharmaceuticals and OTC products to supply participating state and local government facilities including Oregon (solicitation S1070000015802, response deadline March 26, 2026). The MMCAP procurement requires cGMP and Drug Supply Chain Security Act compliance, wholesaler-managed distribution through AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., and insurance coverage including $5,000,000 commercial general liability per occurrence. Neither solicitation explicitly designates set-asides for disadvantaged enterprises.